Sugi Predict

Sugi Predict / Compounds / SCHEMBL736098

SCHEMBL736098

SCHEMBL736098

O=C(O)CCCc1ccc[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 2/20 0.52
▸ HDAC4 P56524 2/20 0.52
▸ HDAC1 Q13547 2/20 0.52
▸ HDAC7 Q8WUI4 2/20 0.52
▸ HDAC2 Q92769 2/20 0.52
▸ HDAC10 Q969S8 2/20 0.52
▸ HDAC11 Q96DB2 2/20 0.52
▸ HDAC8 Q9BY41 2/20 0.52
▸ HDAC6 Q9UBN7 2/20 0.52
▸ HDAC9 Q9UKV0 2/20 0.52
▸ HDAC5 Q9UQL6 2/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ ADRA1A P35348 1/20 0.52
▸ SLC6A3 Q01959 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ TSHR P16473 2/20 0.50
▸ MAPT P10636 1/20 0.44
▸ RXFP1 Q9HBX9 1/20 0.44
▸ TBXAS1 P24557 3/20 0.44
▸ CYP1A2 P05177 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27608146 0.94 MAPT (0.52) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1471746 0.93 MAPT (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL2932213 0.93 MAPT (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL736113 0.93 MAPT (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL30661655 0.93 MAPT (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL735832 0.88 TSHR (0.53) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL9680709 0.86 MAPT (0.45) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL7878183 0.85 MPO (0.42) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL28269903 0.84 EPHX2 (0.50) TSHRMAPTRXFP1CYP1A2FFAR1
SCHEMBL22660139 0.83 TSHR (0.46) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10167501-B2 Methods and apparatus for quantification of nucleic acid amplification by monitoring impedances AUCKLAND UNISERVICES LIMITED (NZ) 2019-01-01 — — US claimed
US-20160046977-A1 Methods and Apparatus for Amplifying Nucleic Acids AUCKLAND UNISERVICES LIMITED (NZ) 2016-02-18 — — US claimed
US-20080280849-A1 Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2008-11-13 — — US claimed
US-7172874-B2 Diagnostic methods for age related macular degeneration THE CLEVELAND CLINIC FOUNDATION (US) 2007-02-06 — — US claimed
US-20040265924-A1 Diagnostic methods for age related macular degeneration THE CLEVELAND CLINIC FOUNDATION 2004-12-30 — — US claimed
CN-1188478-A Azacycloalcane derivatives, preparation thereof and their applications in therapy SYNTHELABO (FR) 1998-07-22 — — CN claimed
CN-117865945-A 2-aldehyde pyrrole butyric acid derivative, preparation method and application thereof 天津现代创新中药科技有限公司 2024-04-12 — — CN disclosed
CN-113759040-B Cat's claw grass and preparation characteristic map and construction method thereof, and method for measuring content of cat's claw grass and preparation thereof 北京康仁堂药业有限公司 2023-04-07 — — CN disclosed
US-20220023421-A1 METHODS FOR ELICITING SELECTIVE HUMORAL RESPONSES UNIVERSITY OF MIAMI (US) 2022-01-27 — — US disclosed
CN-113759040-A Cat's claw grass and preparation characteristic map and construction method thereof, and method for measuring content of cat's claw grass and preparation thereof 北京康仁堂药业有限公司 2021-12-07 — — CN disclosed
US-10987408-B2 Compositions and methods for modulating toll-like receptor 2 activation THE CLEVELAND CLINIC FOUNDATION (US) 2021-04-27 — — US disclosed
US-20190184013-A1 COMPOSITIONS FOR SELECTIVE HUMORAL RESPONSES AND METHODS OF USE THEREOF UNIVERSITY OF MIAMI 2019-06-20 — — US disclosed
EP-3463297-A1 COMPOSITIONS FOR SELECTIVE HUMORAL RESPONSES AND METHODS OF USE THEREOF University of Miami (US) 2019-04-10 — — EP disclosed
CN-1258528-C Method for the production of 2-pyrrolidone BASF AG (DE) 2006-06-07 — — CN disclosed
US-20040265924-A1 Diagnostic methods for age related macular degeneration THE CLEVELAND CLINIC FOUNDATION 2004-12-30 — — US disclosed
CN-1551868-A Method for the production of 2-pyrrolidone �����ɷ� 2004-12-01 — — CN disclosed
WO-2003099801-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2003-12-04 — — WO disclosed
EP-0101004-B2 PROCESS FOR PREPARING 4-OXO-4, 5, 6, 7-TETRAHYDROINDOLE DERIVATIVE SAGAMI CHEMICAL RESEARCH CENTER (JP) 1991-10-16 — — EP disclosed
EP-0101004-B1 PROCESS FOR PREPARING 4-OXO-4, 5, 6, 7-TETRAHYDROINDOLE DERIVATIVE SAGAMI CHEMICAL RESEARCH CENTER (JP) 1987-01-21 — — EP disclosed
EP-0101004-A1 Process for preparing 4-oxo-4, 5, 6, 7-tetrahydroindole derivative SAGAMI CHEMICAL RESEARCH CENTER (JP) 1984-02-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10987408-B2 Compositions and methods for modulating toll-like receptor 2 activation TLR2, TLR3, TLR1 HDAC3 1399/4885HDAC4 1258/4885HDAC1 1250/4885
US-20080280849-A1 Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents CTSL, CDKL1, QTRT2 HDAC3 1784/4885HDAC4 710/4885HDAC1 611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.